Secondary Hyperparathyroidism in Haemodialysis Patients

Secondary Hyperparathyroidism in Haemodialysis Patients


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

₹ 5,066

Availability: Out of stock


Delivery :

5% Cashback on all Orders paid using MobiKwik Wallet T&C

Free Krispy Kreme Voucher on all Orders paid using UltraCash Wallet T&C
Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description

Secondary hyperparathyroidism (SHPT) develops frequently in patients with “End Stage Renal Disease” because the production of 1, 25 (OH) 2- vitamin D (calcitriol) decreases in the kidneys. That’s why patients may develop osteodystrophy or osteomalacia. The functional role of vitamin D3 under normal body condition is to regulate secretion of parathyroid hormone (PTH) synthesis and release. Parameters such as calcium, phosphate and vitamin D3 act upon PTH. In normal subjects, the homeostasis of these parameters is strongly interconnected but in renal failure, the metabolism of each of these parameters may be deregulated. The diseased kidney is unable to produce vital hormone that is called erythropoietin which increases synthesis of red blood cells. The anemic condition is seen in CKD (chronic kidney disease) because erythropoietin production become reduced. In Pakistan, CKD patients are continuously increasing annually. We conducted a blood and serosurvey study in Lahore metropolitan city of Punjab, Pakistan to see the co-relation between SHPT and CKD. This epidemiological research of public health will be beneficial for onward broad demographic surveillance programs.

Product Specifications
SKU :COC36216
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-07-31
0 Review(s)